December 23, 2020

Fujimori Kogyo Co., Ltd.

T-TAS 01 Wins Hematology and Coagulation Division Best Abstract Award from the American Association for Clinical Chemistry

Fujimori Kogyo Co., Ltd. (Head Office: Bunkyo-ku, Tokyo, Representative Director and President: Eishi Fuyama) is pleased to announce that at the 2020 annual meeting of the American Association for Clinical Chemistry (AACC 2020), a presentation on our T-TAS 01 (Total Thrombus-formation Analysis System) won the Hematology and Coagulation Division Best Abstract in Coagulation Award.

The report described the T-TAS 01 system's sensitivity and specificity for detecting primary hemostasis abnormalities in patients taking antiplatelet therapy or having a diagnosis of a primary hemostasis defects.

Conference Name: AACC 2020 (American Association for Clinical Chemistry) Annual Scientific Meeting & Clinical Lab Expo
Dates: Dec. 13-17, 2020 (held online)
Title Number: B-136
Title: Comparison of the T-TAS 01 PL Assay with PFA-100 for Assessment of Primary Hemostatic Function
Award: Hematology and Coagulation Division Best Abstract Award

To evaluate the performance of T-TAS 01, the T-TAS 01 PL assay was performed on 252 subjects, including healthy subjects that were screened for hemostasis abnormalities. Measurements were also made with the PFA-100, a platelet function testing instrument used in Europe and the United States.

The results showed that the T-TAS 01 PL assay is highly sensitive and specific for the evaluation of primary hemostatic capacity. The T-TAS 01 is a testing method based on a new principle and it has been shown to be useful for the assessment of overall primary hemostatic function in patients with defects in primary hemostatic function or in the setting of antiplatelet therapy use.



About the T-TAS 01

Our independently developed T-TAS® (Total Thrombus-formation Analysis System) is the first instrument in the world for the quantification of the thrombus forming ability of the blood under physiological flow conditions. T-TAS® 01 has been sold in Europe since March 2019 through seven distributors covering 17 countries. In February 2020, it was cleared by the US Food and Drug Administration (FDA) for in vitro diagnosis use. It has been highly evaluated by researchers and physicians in the field of blood clotting and hemostasis in Japan, Europe, and the United States.

The T-TAS 01 PL chip is a dedicated reagent that can analyze and evaluate platelet thrombus formation in patients receiving antiplatelet therapy—including aspirin, clopidogrel, prasugrel and ticagrelor—and in patients with primary hemostasis abnormalities such as Glanzmann's thrombasthenia or von Willebrand's Disease.

Our company will contribute to improving the quality of medical care in the field of thrombosis and hemostasis by providing this instrument and its chips to a wide range of clinical sites, and we will also work on the development of medical equipment that can be used with greater comfort and peace of mind by medical professionals.

Website: T-TAS site https://www.t-tas.info

Reference:

The AACC's (American Association for Clinical Chemistry) Annual Scientific Meeting, held annually in the United States, is one of the world's largest academic conferences on clinical testing. It is attended by more than 200,000 physicians, healthcare professionals, and researchers, and has significant influence in the field of clinical testing.

Related Inquiries

Business Planning Department, Advanced Medical Business Promotion Department,
Fujimori Kogyo Co., Ltd.
Phone: +81-3-5804-4238